We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
CONMED
CNMD
$1.55B
| $5.76M | 0.01% |
+80,000
| New | +$5.57M |
|
|
STSA
602
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $5.75M | 0.01% |
200,000
-493,625
| -71% | -$11.4M |
|
603
Kilroy Realty
KRC
$4.54B
| $5.74M | 0.01% |
+97,843
| New | +$5.93M |
|
|
SEE
604
DELISTED
Sealed Air
SEE
| $5.69M | 0.01% |
173,175
-3,100
| -2% | -$93.1K |
|
605
Sutro Biopharma
STRO
$416M
| $5.63M | 0.01% |
72,500
+30,000
| +71% | +$2.88M |
|
606
Bath & Body Works
BBWI
$4.23B
| $5.62M | 0.01% |
464,632
+71,324
| +18% | +$795K |
|
607
Bristow Group
VTOL
$1.35B
| $5.57M | 0.01% |
+400,000
| New | +$4.27M |
|
|
ALE
608
DELISTED
Allete
ALE
| $5.46M | 0.01% |
+100,000
| New | +$5.67M |
|
|
AUY
609
DELISTED
Yamana Gold, Inc.
AUY
| $5.46M | 0.01% |
1,000,000
-2,000,000
| -67% | -$9.56M |
|
610
Arrowhead Research
ARWR
$12.1B
| $5.4M | 0.01% |
125,000
-25,000
| -17% | -$882K |
|
|
CKH
611
DELISTED
Seacor Holdings Inc.
CKH
| $5.38M | 0.01% |
+190,000
| New | +$5.19M |
|
|
NVRO
612
DELISTED
NEVRO CORP.
NVRO
| $5.38M | 0.01% |
45,000
-55,000
| -55% | -$6.52M |
|
|
CLLS
613
Cellectis
CLLS
$277M
| $5.34M | 0.01% |
300,000
-250,000
| -45% | -$3.8M |
|
614
News Corp Class A
NWSA
$15.1B
| $5.29M | 0.01% |
446,482
+9,512
| +2% | +$102K |
|
615
Curtiss-Wright
CW
$27.6B
| $5.25M | 0.01% |
+58,799
| New | +$5.6M |
|
616
Tradeweb Markets
TW
$21.5B
| $5.11M | 0.01% |
87,894
-5,000
| -5% | -$288K |
|
617
Paylocity
PCTY
$7.48B
| $5.11M | 0.01% |
+35,000
| New | +$4.07M |
|
618
Select Water Solutions
WTTR
$2.29B
| $5.1M | 0.01% |
1,040,588
-175,000
| -14% | -$802K |
|
|
DRNA
619
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.08M | 0.01% |
200,000
-50,000
| -20% | -$1.08M |
|
620
SelectQuote
SLQT
$133M
| $5.07M | 0.01% |
+200,000
| New | +$5.37M |
|
621
Alaska Air
ALK
$5.6B
| $5.06M | 0.01% |
139,500
-2,600
| -2% | -$84.7K |
|
622
AGNC Investment
AGNC
$12.6B
| $5M | 0.01% |
+387,363
| New | +$4.86M |
|
623
Armstrong World Industries
AWI
$7.58B
| $4.94M | 0.01% |
+63,423
| New | +$4.81M |
|
|
AYX
624
DELISTED
Alteryx Inc
AYX
| $4.93M | 0.01% |
+30,000
| New | +$3.89M |
|
625
Lincoln National
LNC
$8.82B
| $4.92M | 0.01% |
133,861
-93,500
| -41% | -$3.29M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.